AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12499051 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 8-hydroxyguanosine (8-OHG) concentrations in CSF and serum
Number of subjects: 0
Study 10817793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (3 courses)
Number of subjects: 688
Study 10817793 — intervention group
Group type: COMPARATOR
Intervention: Not receiving cisplatin-based chemotherapy (control group)
Number of subjects: 688
Study 10817793 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 688
Study 8653493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) toothpaste
Number of subjects: 28
Study 8653493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoamidopropyl‐betaine (CAPB) toothpaste
Number of subjects: 28
Study 8653493 — intervention group
Group type: COMPARATOR
Intervention: Detergent-free toothpaste
Number of subjects: 28
Study 1511812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenating mouthguard (3 liters/min)
Number of subjects: 263
Study 1511812 — intervention group
Group type: COMPARATOR
Intervention: Standard mouthguard
Number of subjects: 263
Study 6149824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise systolic blood pressure recovery ratios at 1, 2, and 3 minutes after exercise in normal subjects
Number of subjects: 87
Study 6149824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise systolic blood pressure recovery ratios at 1, 2, and 3 minutes after exercise in patients with CAD
Number of subjects: 87
Study 6149824 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal recovery ratios in patients with CAD
Number of subjects: 87
Study 6149824 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise test on placebo and beta-blocker in patients with CAD
Number of subjects: 87
Study 29530353 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff
Number of subjects: 1188
Study 29530353 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRings
Number of subjects: 1188
Study 29530353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HD colonoscopy
Number of subjects: 1188
Study 29530353 — intervention group
Group type: COMPARATOR
Intervention: FUSE
Number of subjects: 1188
Study 27547026 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 198
Study 27547026 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar electrocautery
Number of subjects: 198
Study 24317453 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 8
Study 24317453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23621628 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5‐FU (5.0 mg/0.5 mL)
Number of subjects: 36
Study 23621628 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with 5‐FU (5.0 mg/0.5 mL)
Number of subjects: 36
Study 23621628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 20721903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 24
Study 20721903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (facilitate coping or increase sense of control)
Number of subjects: 24
Study 20721903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18845667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow cells (BMCs)
Number of subjects: 80
Study 18845667 — intervention group
Group type: COMPARATOR
Intervention: Placebo medium
Number of subjects: 80
Study 17029631 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine and AII antagonist
Number of subjects: 0
Study 17029631 — intervention group
Group type: COMPARATOR
Intervention: AII antagonist
Number of subjects: 0
Study 15451146 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1778
Study 15451146 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 1778
Study 11176090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand intubation without cricoid pressure
Number of subjects: 60
Study 11176090 — intervention group
Group type: COMPARATOR
Intervention: Lightwand intubation with cricoid pressure
Number of subjects: 60
Study 9038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg (F2.5)
Number of subjects: 115
Study 9038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg (F5)
Number of subjects: 115
Study 9038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine Retard 10 mg (N20)
Number of subjects: 115
Study 9038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine Retard 20 mg (N40)
Number of subjects: 115
Study 8430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 59
Study 8430728 — intervention group
Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 59
Study 8430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (iris-plane phacoemulsification)
Number of subjects: 59
Study 8430728 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (iris-plane phacoemulsification)
Number of subjects: 59
Study 8430728 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (posterior-chamber phacoemulsification)
Number of subjects: 59
Study 2885573 — intervention group
Group type: EXPERIMENTAL
Intervention: lymphoblastoid interferon for six months
Number of subjects: 46
Study 2885573 — intervention group
Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 46
Study 2885573 — intervention group
Group type: EXPERIMENTAL
Intervention: lymphoblastoid interferon
Number of subjects: 46
Study 29524976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroless-URS
Number of subjects: 154
Study 29524976 — intervention group
Group type: COMPARATOR
Intervention: Standard-URS
Number of subjects: 154
Study 26670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message reminder (including first name and contact information)
Number of subjects: 539
Study 26670912 — intervention group
Group type: COMPARATOR
Intervention: Generic text message reminder
Number of subjects: 539
Study 26670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message reminder for patients with recent chlamydia
Number of subjects: 539
Study 26670912 — intervention group
Group type: COMPARATOR
Intervention: Generic text message reminder for patients with recent chlamydia
Number of subjects: 539
Study 26670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message reminder for patients with recent gonorrhoea
Number of subjects: 539
Study 26670912 — intervention group
Group type: COMPARATOR
Intervention: Generic text message reminder for patients with recent gonorrhoea
Number of subjects: 539
Study 26670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message reminder for MSM
Number of subjects: 539
Study 26670912 — intervention group
Group type: COMPARATOR
Intervention: Generic text message reminder for MSM
Number of subjects: 539
Study 26670912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message reminder
Number of subjects: 539
Study 24528942 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 17
Study 24528942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22566415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder/recall (2 letters and 2 telephone calls)
Number of subjects: 800
Study 22566415 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 800
Study 20627749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural tenting
Number of subjects: 48
Study 20627749 — intervention group
Group type: COMPARATOR
Intervention: No tenting (Control)
Number of subjects: 48
Study 19149363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili group
Number of subjects: 50
Study 19149363 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 50
Study 15735115 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial tumors
Number of subjects: 8422
Study 15735115 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial tumors (node-negative cohort)
Number of subjects: 8422
Study 12877895 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT (Blood Cell Transplantation)
Number of subjects: 101
Study 12877895 — intervention group
Group type: COMPARATOR
Intervention: BMT (Bone Marrow Transplantation)
Number of subjects: 101
Study 10587385 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with urokinase using the pulse‐spray technique (ENDO)
Number of subjects: 80
Study 10587385 — intervention group
Group type: COMPARATOR
Intervention: Surgical thrombectomy with or without graft revision (SURG)
Number of subjects: 80
Study 10587385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ENDO and SURG groups
Number of subjects: 80
Study 8692739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast sodium (3, 9, and 18 mg)
Number of subjects: 12
Study 8692739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast sodium (10 mg)
Number of subjects: 12
Study 8692739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast sodium (9 mg) in females
Number of subjects: 12
Study 8692739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast sodium (10 mg) in females
Number of subjects: 12
Study 1919803 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 54
Study 1919803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate (FeAC; equivalent to 6 mg iron) plus vitamin C for 9 weeks
Number of subjects: 54
Study 1919803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 50% VO2 max
Number of subjects: 54
Study 6627292 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 37
Study 6627292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 37
Study 6627292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30638739 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-oil lipid emulsion (30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil) administered continuously for 5 days, FO dose of 0.09-0.22 g/kg body weight.
Number of subjects: 75
Study 30638739 — intervention group
Group type: COMPARATOR
Intervention: 100% soybean oil lipid emulsion administered continuously for 5 days.
Number of subjects: 75
Study 30638739 — intervention group
Group type: COMPARATOR
Intervention: Four-oil lipid emulsion (SG) vs 100% soybean oil (CG)
Number of subjects: 75
Study 30680401 — intervention group
Group type: EXPERIMENTAL
Intervention: SPR periodontal basic treatment
Number of subjects: 80
Study 30680401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 80
Study 26768855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Transcranial Doppler (TCD) measurements
Number of subjects: 89
Study 26768855 — intervention group
Group type: COMPARATOR
Intervention: No Transcranial Doppler (TCD) measurements
Number of subjects: 89
Study 26075751 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of diet (low-carbohydrate diet [LCD] or low-fat diet [LFD]) with counseling for 48 weeks
Number of subjects: 207
Study 26075751 — intervention group
Group type: COMPARATOR
Intervention: Random assignment to a diet (LCD or LFD) with counseling for 48 weeks
Number of subjects: 207
Study 22136963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing eicosapentaenoic and docosahexaenoic acid
Number of subjects: 32
Study 22136963 — intervention group
Group type: COMPARATOR
Intervention: Control (no lipid emulsion with eicosapentaenoic and docosahexaenoic acid)
Number of subjects: 32
Study 20617588 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum immunoglobulin 400 mg/(kg x d) infusion qd for 7 days
Number of subjects: 220
Study 20617588 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone tablets 1 mg/(kg x d), 2 times/d for 2 weeks, then gradually reducing; all-trans retinoic acid 10 mg, 3 times a day, oral
Number of subjects: 220
Study 20617588 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum immunoglobulin treatment
Number of subjects: 220
Study 18765182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with physiotherapy (Group-1)
Number of subjects: 46
Study 18765182 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone (Group-2)
Number of subjects: 46
Study 18765182 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone (Group-3)
Number of subjects: 46
Study 15692600 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-I-converting enzyme inhibitors (ACEI), n=25 (15%)
Number of subjects: 168
Study 15692600 — intervention group
Group type: COMPARATOR
Intervention: Non-ACEI group, n=143 (85%)
Number of subjects: 168
Study 15692600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertension taking ACEI
Number of subjects: 168
Study 15692600 — intervention group
Group type: COMPARATOR
Intervention: Patients with hypertension not taking ACEI
Number of subjects: 168
Study 11833075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iodized oil TACE (more than 20 mL Lipiodol)
Number of subjects: 473
Study 11833075 — intervention group
Group type: COMPARATOR
Intervention: Routine dose iodized oil TACE (5-15 mL Lipiodol)
Number of subjects: 473
Study 10362425 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at doses of < or =5 ppm
Number of subjects: 26
Study 10362425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged inhaled nitric oxide at doses of < or =20 ppm
Number of subjects: 26
Study 7722713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (specifics on dosage and duration not available)
Number of subjects: 356
Study 7722713 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation
Number of subjects: 356
Study 2040466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) three times a day for three days
Number of subjects: 34
Study 2040466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6389470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (5 mg/kg three times daily for five days)
Number of subjects: 40
Study 6389470 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir (400 mg five times daily for five days)
Number of subjects: 40
Study 31302066 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 73
Study 31302066 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint and botulinum toxin injections
Number of subjects: 73
Study 31302066 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint
Number of subjects: 73
Study 29787484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence‐accommodative therapy (n = 4)
Number of subjects: 7
Study 29787484 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 3)
Number of subjects: 7
Study 27281233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD) and antibiotic‐loaded bone cement
Number of subjects: 46
Study 27281233 — intervention group
Group type: COMPARATOR
Intervention: Vacuum sealing drainage (VSD) only
Number of subjects: 46
Study 24932979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine plus 0.5 M mannitol (2.90 mL solution: 1.84 mL lidocaine with 18.4 μg epinephrine + 1.06 mL mannitol)
Number of subjects: 41
Study 24932979 — intervention group
Group type: COMPARATOR
Intervention: Control: Lidocaine with epinephrine (1.84 mL solution: 36.8 mg lidocaine with 18.4 μg epinephrine)
Number of subjects: 41
Study 24932979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine plus 0.5 M mannitol
Number of subjects: 41
Study 24932979 — intervention group
Group type: COMPARATOR
Intervention: Control: Lidocaine with epinephrine
Number of subjects: 41
Study 22227226 — intervention group
Group type: EXPERIMENTAL
Intervention: robenacoxib (2 mg/kg)
Number of subjects: 96
Study 22227226 — intervention group
Group type: COMPARATOR
Intervention: meloxicam (0.3 mg/kg)
Number of subjects: 96
Study 20541324 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure group (20‐25 mmHg)
Number of subjects: 17
Study 20541324 — intervention group
Group type: COMPARATOR
Intervention: Low pressure group (10‐15 mmHg)
Number of subjects: 17
Study 20064644 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational learning with a model present
Number of subjects: 20
Study 20064644 — intervention group
Group type: COMPARATOR
Intervention: Ghost condition (no model present)
Number of subjects: 20
Study 15642076 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 505
Study 15642076 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 505
Study 12097664 — intervention group
Group type: EXPERIMENTAL
Intervention: High amylose cornstarch (AM) diet
Number of subjects: 24
Study 12097664 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cornstarch (AP) diet
Number of subjects: 24
Study 9741192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastopathy patients (group M)
Number of subjects: 65
Study 9741192 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (group K)
Number of subjects: 65
Study 9741192 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal patients with mastopathy
Number of subjects: 65
Study 7799476 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.5 g kg‐1 body mass)
Number of subjects: 8
Study 7799476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g of calcium carbonate and 4 mg of sodium chloride)
Number of subjects: 8
Study 2899186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 120
Study 2899186 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 120
Study 2899186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pimozide and lithium
Number of subjects: 120
Study 2899186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31957542 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cues with clear audio
Number of subjects: 10
Study 31957542 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues with clear audio
Number of subjects: 10
Study 31957542 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cues with incongruent auditory information
Number of subjects: 10
Study 31957542 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded audio conditions
Number of subjects: 10
Study 29427725 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week knee extensor strengthening exercise program
Number of subjects: 97
Study 29427725 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 97
Study 30650290 — intervention group
Group type: EXPERIMENTAL
Intervention: Guishen Zhiyang Recipe (GZR)
Number of subjects: 90
Study 30650290 — intervention group
Group type: COMPARATOR
Intervention: Fuyang Granule (FG)
Number of subjects: 90
Study 24848384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion (6 μg/kg/minute)
Number of subjects: 60
Study 24848384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 23731195 — intervention group
Group type: EXPERIMENTAL
Intervention: Active formulation containing licochalcone A, l-carnitine and 1,2-decanediol applied twice daily for 8 weeks
Number of subjects: 60
Study 23731195 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied twice daily for 8 weeks
Number of subjects: 60
Study 20008943 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) or venlafaxine, with or without cognitive-behavioral therapy (CBT)
Number of subjects: 155
Study 20008943 — intervention group
Group type: EXPERIMENTAL
Intervention: FKBP5 genotypes (rs1360780TT and rs3800373GG)
Number of subjects: 155
Study 18171951 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted minimally invasive total knee arthroplasty
Number of subjects: 108
Study 18171951 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 108
Study 15732619 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-rich spa water (Spatone)
Number of subjects: 102
Study 15732619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 102
Study 12632268 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive aortic surgery (MIAS)
Number of subjects: 80
Study 12632268 — intervention group
Group type: COMPARATOR
Intervention: Standard open aortic procedures
Number of subjects: 80
Study 10818263 — intervention group
Group type: EXPERIMENTAL
Intervention: NPY 50 microg
Number of subjects: 20
Study 10818263 — intervention group
Group type: EXPERIMENTAL
Intervention: NPY 100 microg
Number of subjects: 20
Study 10818263 — intervention group
Group type: EXPERIMENTAL
Intervention: NPY (both doses)
Number of subjects: 20
Study 8815021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxim 1500 mg administered 30 min before the procedure (Group A, n = 49)
Number of subjects: 99
Study 8815021 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Group B, n = 50)
Number of subjects: 99
Study 1814657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 19
Study 1814657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6441721 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) infusion in controls
Number of subjects: 0
Study 6441721 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) infusion in hyperprolactinaemics
Number of subjects: 0
Study 6441721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine pretreatment
Number of subjects: 0
Study 6441721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethazone pretreatment
Number of subjects: 0
Study 31256116 — intervention group
Group type: EXPERIMENTAL
Intervention: WESIHAT 2.0© (30 minutes per day, 4 days per week for six months)
Number of subjects: 50